1. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma
   JUN-DONG ZHOU et al, 2013, Oncology Reports CrossRef
2. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma
   Amanda J. Craig et al, 2021, PLOS Genetics CrossRef
3. Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1
   Junichiro Miyazaki et al, 2017, Translational Oncology CrossRef
4. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
   Remy Thomas et al, 2018, Frontiers in Immunology CrossRef
5. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4+ T-cells Expressing Granzyme B in a Mouse Model of Melanoma
   Weiming Yang et al, 2021, Anti-Cancer Agents in Medicinal Chemistry CrossRef
6. Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area’
   F Grizzi et al, 2016, British Journal of Cancer CrossRef
7. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression
   J Liang et al, 2013, British Journal of Cancer CrossRef
8. Current status and perspectives of immune-based therapies for hepatocellular carcinoma
   Maridi Aerts, 2016, World Journal of Gastroenterology CrossRef
9. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors
   Timothy T. Spear et al, 2016, Cancer Immunology, Immunotherapy CrossRef
10. Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions
    Fei Li et al, 2020, Journal of Cellular Physiology CrossRef
11. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in head and neck cancer
    Simon Laban et al, 2014, International Journal of Cancer CrossRef
12. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma
    Mahnaz Seifi-Alan et al, 2018, Immunotherapy CrossRef
13. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy
    Ali Esfandiary et al, 2015, Immunotherapy CrossRef
14. Potential therapeutic value of dendritic cells loaded with NY-ESO-1 protein for the immunotherapy of advanced hepatocellular carcinoma
    YUQING CHEN et al, 2013, International Journal of Molecular Medicine CrossRef
15. Adaptive immunity in the liver
    Zongwen Shuai et al, 2016, Cellular & Molecular Immunology CrossRef
16. The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies
    Gaetano Bertino et al, 2015, BioMed Research International CrossRef
17. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma
    Jessica A Hemminger et al, 2014, Modern Pathology CrossRef
18. Current Status of Gene Therapy in Hepatocellular Carcinoma
    Saranya Chidambaranathan Reghupaty et al, 2019, Cancers CrossRef
19. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms
    Jessica A Hemminger et al, 2013, Modern Pathology CrossRef